https://www.selleckchem.com/pr....oducts/oprozomib-onx
These results demonstrate that the PTSHPβCD complex has a dose-dependent antioxidant mechanism that results in improved cardiac function in experimental right heart failure. Our results open a field of possibilities to PTS administration as new therapeutic approach to conventional therapy for right ventricular dysfunction. Novelty bullets - Pterostilbene complexed with hydroxypropyl-β-cyclodextrin could be a new therapeutic approach; - Pterostilbene complexed with hydroxypropyl-β-cyclodextrin re-establishes redox homeostasis,
Aimer
Commentaire
Partagez
